Copertina

Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Chelsi M. Almodóvar‐Rivera, Ira Tandon, Ramesh Mudududdla, Paulina N. Esguerra, Kevin Lucio‐Acero, Weiping Tang
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	ChemMedChem
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy
di: Yerim Jin, et al.
Pubblicazione: (2024)

Development of C646‐Based Proteolysis Targeting Chimeras Degraders of the Lysine Acetyltransferases CBP and p300
di: Francesco Fiorentino, et al.
Pubblicazione: (2025)

Insights Into Vepdegestrant (ARV‐471): The First‐in‐Class Estrogen Receptor Proteolysis‐Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer
di: Chao Tang, et al.
Pubblicazione: (2026)

Replacing a Cereblon Ligand by a DDB1 and CUL4 Associated Factor 11 (DCAF11) Recruiter Converts a Selective Histone Deacetylase 6 PROTAC into a Pan‐Degrader
di: Felix Feller, et al.
Pubblicazione: (2025)

Ligand‐Induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4
di: Daria Kotlarek, et al.
Pubblicazione: (2026)

Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation
di: Jinmin Miao, et al.
Pubblicazione: (2024)

A Facile Protocol for C(sp 2 )–C(sp 3 ) Bond Formation Reactions Toward Functionalized E3 Ligase Ligands
di: Anita Maksutova, et al.
Pubblicazione: (2025)

Developing Dynamic Structure‐Based Pharmacophore and ML‐Trained QSAR Models for the Discovery of Novel Resistance‐Free RET Tyrosine Kinase Inhibitors Through Extensive MD Trajectories and NRI Analysis
di: Ehsan Sayyah, et al.
Pubblicazione: (2024)

Inhibition Clathrin Mediated Endocytosis: Pitstop 1 and Pitstop 2 Chimeras
di: Kate Prichard, et al.
Pubblicazione: (2024)

Small‐Molecule KRAS Inhibitors by Tyrosine Covalent Bond Formation
di: Alexander D. Landgraf, et al.
Pubblicazione: (2025)

Design and Evaluation of Tyrosine‐Rich Antimicrobial Peptides With Quadruple Repeating Units
di: Heiya Na, et al.
Pubblicazione: (2026)

Small Molecule Kinase Inhibitors with In Vitro β‐Hematin Formation and Plasmodium falciparum Protein Kinase G Inhibitory Activity Identified Using Machine Learning
di: Jessica L. Thibaud, et al.
Pubblicazione: (2026)

Binding‐Site Switch for Protein Kinase CK2 Inhibitors
di: Dylan Grenier, et al.
Pubblicazione: (2025)

Cyclin‐Dependent Kinase 11: Cellular Functions and Potential Therapeutic Applications
di: Janhabee Shrestha, et al.
Pubblicazione: (2025)

Structural Analysis of the Macrocyclic Inhibitor BI‐4020 Binding to EGFR Kinase
di: Tyler S. Beyett, et al.
Pubblicazione: (2024)

Recent Advances of Quinoline‐Based Small Molecules as Kinase Inhibitors (2020–2024)
di: Sara Sultan, et al.
Pubblicazione: (2025)

Emerging Trends in Quinoxaline‐Based Analogs as Protein Kinase Inhibitors: Structural Developments and SAR Insights
di: Shivani, et al.
Pubblicazione: (2024)

GDF15 Analogues Acting as GFRAL Ligands
di: Andrea Di Santo, et al.
Pubblicazione: (2025)

Decoding Class III Phosphatidylinositol 3‐Kinase (PtdIns3K) Regulation: Mechanistic Insights and Therapeutic Opportunities
di: Qiao Liu, et al.
Pubblicazione: (2026)

Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Cavα2δ‐1 Subunit of Voltage‐Gated Calcium Channel and the μ‐Opioid Receptor
di: Anita Wegert, et al.
Pubblicazione: (2024)

Towards the Targeted Protein Degradation of PRMT1
di: Poppy L. Martin, et al.
Pubblicazione: (2024)

Investigating the Ligand‐Binding Properties of N‐arylbenzimidazoles as Novel Elastase Inhibitors
di: Giovanna Pitasi, et al.
Pubblicazione: (2025)

Targeting Inflammatory and Oncogenic Pathways: Cyclooxygenase‐2, Epidermal Growth Factor Receptor, and p38 Mitogen‐Activated Protein Kinase Inhibition by Pyrazolone Derivatives
di: Sevde Nur Biltekin Kaleli, et al.
Pubblicazione: (2026)

Ligand Screening and Discovery Using Cocktail Soaking and Automated Microcrystal Electron Diffraction
di: Jieye Lin, et al.
Pubblicazione: (2025)

Structure‐ and Ligand‐Based Discovery of Novel 3‐Chymotrypsin‐Like Protease Nonpeptidomimetic Hits
di: Sabrina Silva‐Mendonça, et al.
Pubblicazione: (2026)

Fluorescence Detection of DNA/RNA G‐Quadruplexes (G4s) by Twice‐as‐Smart Ligands
di: Jiri Ledvinka, et al.
Pubblicazione: (2025)

The Evaluation of Glyceryl C3‐Azolyl‐Thiogalactosides as Galectin‐1 and Galectin‐3 Ligands
di: Vít Prouza, et al.
Pubblicazione: (2025)

An Effective Reaction‐Based Virtual Screening Method to Discover New CDK8 Ligands
di: Wei Chen, et al.
Pubblicazione: (2025)

Cyclic Peptides Radiopharmaceuticals: A Concise Review of Ligand Identification, Radiolabeling, and Clinical Progress
di: Xiushuang Yuan, et al.
Pubblicazione: (2026)

Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation
di: Junhyeong Yim, et al.
Pubblicazione: (2024)

Structural Basis of Conformational Dynamics in the PROTAC‐Induced Protein Degradation
di: Hongtao Zhao
Pubblicazione: (2024)

Marine‐Inspired Spirooxindole PIM‐1 Kinase Inhibitors Endowed with Concomitant TRKA/CDK2 Inhibition for Multifaceted Non‐Small Cell Lung Cancer Apoptotic Induction
di: Refaah M. Al‐Jassas, et al.
Pubblicazione: (2025)

Investigating the C2 Modulation of the Imidazo[1,2‐a]pyrazine‐Based Hit Compound CTN1122: Synthesis, in vitro Antileishmanial Activity, Cytotoxicity and Casein Kinase 1 Inhibition
di: Lhana Tisseur, et al.
Pubblicazione: (2025)

PROTAC‐Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies
di: Ambati Himaja, et al.
Pubblicazione: (2025)

Machine Learning‐Driven Discovery of GABA‐A Ligands with Pronounced Neuroprotective Efficacy and Resistance to P‐gp Efflux
di: Katarzyna Szafrańska, et al.
Pubblicazione: (2025)

Protonation Effects in Protein‐Ligand Complexes – A Case Study of Endothiapepsin and Pepstatin A with Computational and Experimental Methods
di: Helge Vatheuer, et al.
Pubblicazione: (2025)

Development of Carborane‐Based Halogenated Naphthyridinone‐Analogues as Cannabinoid Receptor Type 2 (CB 2 R) Ligands
di: Lea Ueberham, et al.
Pubblicazione: (2025)

One‐Step Assembly of Homogeneous DAR4 ADCs via a Traceless Fc Ligand‐Directed Acylation Strategy
di: Yue Zeng, et al.
Pubblicazione: (2026)

Discovery and in vitro Evaluation of Novel Serotonin 5‐HT2A Receptor Ligands Identified Through Virtual Screening
di: Agata Zięba, et al.
Pubblicazione: (2024)

Development of a NanoBRET Assay Platform to Detect Intracellular Ligands for the Chemokine Receptors CCR6 and CXCR1
di: Max E. Huber, et al.
Pubblicazione: (2024)